Physician profile
Anthony Rizzo
NPI 1194736470
$2,547.82
in general payments reported to CMS, 2019-2025
25 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $86.17 · 2021: $26.32 · 2022: $56.25 · 2023: $485 · 2024: $504 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.28 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $694.02 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $258.55 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $215.98 | 2019-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $189.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $148.04 | 2023-2025 | Rexulti |
| Amgen INC. | $120.52 | 2025 | Repatha |
| Abbott Laboratories | $115.99 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $92.03 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $76.34 | 2019-2023 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $75.18 | 2019 | |
| Ardelyx, INC. | $62.05 | 2024-2025 | Ibsrela |
| Inspire Medical Systems, INC. | $57.41 | 2024-2025 | Inspire |
| Amarin Pharma, INC. | $52.77 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Lundbeck LLC | $46.82 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $45.38 | 2025 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $44.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $41.22 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $32.22 | 2019-2022 | |
| Esperion Therapeutics, INC. | $28.61 | 2023 | Nexletol |
| Merck Sharp & Dohme LLC | $27.54 | 2025 | Verquvo |
| Sumitomo Pharma America, INC. | $26.38 | 2024 | Gemtesa |
| Dexcom, INC. | $20.01 | 2025 | Dexcom G6 Transmitter |
| Misonix INC | $15.16 | 2019 | |
| Allergan, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.